Bence Tasnadi

Despite being the most prevalent primary intraocular cancer in people, uveal melanoma is nevertheless uncommon and sometimes overlooked in public health discourse (1). In the UK, routine eye exams performed in community optometry settings are the main means of detecting uveal melanoma (2). Although this approach makes it possible to detect illness before symptoms appear, it may also lead to unforeseen disparities. Patients from lower socioeconomic status (SES) groups may encounter obstacles that affect disease outcomes by delaying detection.

The tendency of uveal melanoma to progress silently is one of its distinguishing features. Patients with early-stage tumours often have no discomfort or discernible visual abnormalities (3). As a result, rather than after symptom-driven presentation, diagnosis frequently happens by accident during routine eye exams. Thus, routine attendance at eye exams is essential for early detection. However, there is a social pattern to the uptake of routine eye care in the UK, with people from lower socioeconomic backgrounds being far less likely to get regular eye exams (4).

One of the main causes of this inequality is financial obstacles. Although some groups are eligible for NHS-funded eye exams, few people are aware of this, and many patients believe that eye treatment is expensive. The direct cost of an examination, together with indirect costs like childcare, transport, and time off work, may deter people who are not eligible for free eye exams from attending. Even in the absence of symptoms, people may be further discouraged by the idea that an eye examination will lead to advice to buy glasses.

Health-seeking behaviour is also significantly influenced by conflicting life priorities. Socioeconomically disadvantaged people may put immediate issues like work, housing, and family obligations ahead of preventative healthcare. Regular eye exams might not be considered necessary, especially if vision seems unaffected. Socioeconomic hardship has been repeatedly linked to lower health literacy and decreased use of preventive services, which further restricts access to opportunistic illness detection (5).

These obstacles are especially worrisome when uveal melanoma is involved. Improved prognostic outcomes, a lower tumour size at diagnosis, and more eligibility for eye-conserving treatments are all linked to earlier detection (6). On the other hand, delayed diagnosis may lead to larger tumours, a higher chance of local problems, and a higher chance of metastatic dissemination, which is still the main cause of death for uveal melanoma. Socioeconomic disadvantage may directly result in worse results if people from lower SES groups are more likely to present later because they have less access to regular eye care.

This brings up significant moral and legal issues. Equity and universal access are the cornerstones of the NHS, yet relying on opportunistic identification through underutilised services could compromise these goals. Due to uveal melanoma’s rarity, population-wide screening is not practical; nevertheless, increasing equal access to routine eye exams may help lessen detection discrepancies. Wider advantages would probably result from such advancements, such as early detection of other vision-threatening diseases including diabetic retinopathy and glaucoma.

In conclusion, the optometric infrastructure in the UK may unintentionally contribute to inequality even while it allows for the early detection of uveal melanoma. Access to routine eye exams appears to be restricted by lower socioeconomic level, raising the possibility of a delayed diagnosis and worse outcomes. To ensure that early cancer identification is no longer a privilege of the socially advantaged, it is imperative to acknowledge and correct this disparity.

References

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118(9):1881-5.
2. Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt. 2001 Jul;21(4):268-71.
3. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017 Feb;31(2):241-57.
4. Kearney S, Strang NC, Lewsey J, Azuara-Blanco A, Jonuscheit S. Socio-economic differences in accessing NHS spectacles amongst children with differing refractive errors living in Scotland. Eye (Lond). 2022 Apr;36(4):773-80.
5. Marmot M. The Health Gap: The Challenge of an Unequal World: the argument. Int J Epidemiol. 2017 Aug 1;46(4):1312-8.
6. Hu W, Cai Q, Gao J, Hu J, Huang Q, Zhang H, et al. Long-term outcomes and prognostic factors of eye-preserving treatment with particle beam radiotherapy for orbital malignancies. BMC Cancer. 2025 Mar 28;25(1):569.